Dianthus Therapeutics has successfully enrolled 65 patients in its Phase 2 MaGic trial of DNTH103 for generalized Myasthenia Gravis, exceeding the target of 60 patients with top-line results expected in September 2025.
Hesperos' Human-on-a-Chip technology supported Dianthus Therapeutics' Investigational New Drug submission for DNTH103, a monoclonal antibody, to the FDA.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.